WhatPeptide

Survodutide

Survodutide is a dual GLP-1 receptor and glucagon receptor co-agonist in Phase 3 clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH/NASH), showing significant reductions in body weight and liver fat content in Phase 2 results. It represents the next generation of metabolic peptide therapeutics with a dual mechanism.

Moderate evidence Investigational GLP-1/Glucagon Agonist

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Currently in clinical trials — not yet approved for any indication.

Half-life

Approximately 7 days

Dosage range

2.4-6 mg once weekly (phase 3 dosing)

Administration

Subcutaneous injection

Research level

Moderate

How Survodutide works

Survodutide combines GLP-1 receptor agonism for appetite suppression and incretin effects with glucagon receptor stimulation that drives hepatic lipolysis, glycogenolysis, thermogenesis, and fatty acid beta-oxidation. The glucagon component specifically targets hepatic steatosis, making survodutide particularly promising for MASH where reducing liver fat is a primary endpoint. Phase 2 data reported approximately 17-19% body weight reduction over 46 weeks.

Also known as: BI 456906, Dual GLP-1/glucagon agonist

Clinical trial efficacy

Phase 2 dose-finding: max -14.9% body weight at 4.8 mg over 46 weeks (ITT). Also demonstrated significant liver fat reduction in MASH patients.

Research relevance

Fat Loss
Strong research relevance 88

Side effects & safety

Nausea Vomiting Diarrhea Decreased appetite Injection site reactions Pancreatitis (rare but serious) Thyroid C-cell tumors (boxed warning — rodent signal, human relevance uncertain) Potential lean mass loss alongside fat loss

Contraindications

History of medullary thyroid carcinoma
MEN2
Pregnancy
Severe liver disease

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is Survodutide? +
Survodutide is a dual GLP-1 receptor and glucagon receptor co-agonist in Phase 3 clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH/NASH), showing significant reductions in body weight and liver fat content in Phase 2 results. It represents the next generation of metabolic peptide therapeutics with a dual mechanism. Its mechanism of action is supported by moderate clinical and preclinical evidence.
What is Survodutide researched for? +
Survodutide has the strongest research relevance for Fat Loss. Evidence is supported by moderate clinical and preclinical evidence.
What are the side effects of Survodutide? +
Reported side effects include Nausea, Vomiting, Diarrhea, Decreased appetite, Injection site reactions, Pancreatitis (rare but serious), Thyroid C-cell tumors (boxed warning — rodent signal, human relevance uncertain), Potential lean mass loss alongside fat loss. Key contraindications: History of medullary thyroid carcinoma; MEN2; Pregnancy; Severe liver disease.
Is Survodutide FDA approved? +
Survodutide is currently in clinical trials and is not yet approved by the FDA.
How is Survodutide administered? +
Survodutide is typically administered via subcutaneous route. Researched dosage range: 2.4-6 mg once weekly (phase 3 dosing). Half-life: Approximately 7 days.

Explore similar peptides

Mazdutide

Moderate evidence

GLP-1/Glucagon Agonist

Mazdutide is a once-weekly dual GLP-1 receptor and glucagon receptor co-agonist in late-stage clinical development for obesity and type 2 diabetes, showing significant weight loss in Phase 3 trials predominantly conducted in the Asia-Pacific region. The glucagon component adds hepatic fat mobilization and energy expenditure to GLP-1-mediated appetite suppression.

CagriSema

Strong evidence

Amylin/GLP-1 Combination

CagriSema is a fixed-dose co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) that demonstrated superior weight loss to either component alone in Phase 3 REDEFINE trials. The combination targets complementary appetite-regulating pathways simultaneously.

Retatrutide

Preliminary evidence

GLP-1/GIP/Glucagon Agonist

An investigational triple agonist (GLP-1/GIP/glucagon) with large early-stage weight-loss signals in phase 2 studies.

Semaglutide

Strong evidence

GLP-1 Agonist

A long-acting GLP-1 receptor agonist with robust randomized evidence for glycemic control and body-weight reduction.